Which programmed death receptor-1 blocking antibody drugs treat carcinoma, non-small-cell lung?

pharmaranks lists 2 Programmed Death Receptor-1 Blocking Antibody products used for carcinoma, non-small-cell lung, per NIH RxClass drug-classification data — each independently rated and ranked above.

How are these ranked?

By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.

Best Programmed Death Receptor-1 Blocking Antibody for carcinoma, non-small-cell lung

Top-rated pick: Opdivo — pharmaranks score 72/100, the highest of the 2 Programmed Death Receptor-1 Blocking Antibody drugs used for carcinoma, non-small-cell lung, ranked by our independent FDA recall-safety score. Compare them with all treatments for carcinoma, non-small-cell lung or the full Programmed Death Receptor-1 Blocking Antibody class. Not medical advice — always consult a professional.

Quick answer: Of the 2 programmed death receptor-1 blocking antibody drugs we rate for carcinoma, non-small-cell lung, none are yet flagged as generics in our price data, and most are injectable. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for carcinoma, non-small-cell lung; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Other drug classes for carcinoma, non-small-cell lung

Best kinase inhibitor Best topoisomerase inhibitor Best microtubule inhibitor

Top programmed death receptor-1 blocking antibody for carcinoma, non-small-cell lung: 1. Opdivo · 2. Keytruda

Best-rated Programmed Death Receptor-1 Blocking Antibody for carcinoma, non-small-cell lung, ranked by pharmaranks score
#	Drug	Rating	Type	Form	Generic?	Pharmacy pays
1	Opdivo	72/100	Prescription	Injectable	No data	—	View →
2	Keytruda	70/100	Prescription	Injectable	No data	—	View →

Full ranking · 2 drugs

opdivo

PrescriptionFDA-sourced

72/100

Opdivo (Nivolumab) is a programmed death receptor-1 blocking antibody used to treat Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma, Kidney Neoplasms.

(4 data points)

programmed death receptor-1 blocking antibodyurinary bladder neoplasmscarcinoma, non-small-cell lung

Price varies

View details →

keytruda

PrescriptionFDA-sourced

70/100

Keytruda (Pembrolizumab) is a programmed death receptor-1 blocking antibody used to treat Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma.

(3 data points)

programmed death receptor-1 blocking antibodymesothelioma, malignantbiliary tract neoplasms

Price varies

View details →

Frequently asked

What is the best programmed death receptor-1 blocking antibody for carcinoma, non-small-cell lung?: By our independent recall-safety rating — not an efficacy measure — opdivo ranks highest among Programmed Death Receptor-1 Blocking Antibody drugs used for carcinoma, non-small-cell lung. Always consult a professional.
Which programmed death receptor-1 blocking antibody drugs treat carcinoma, non-small-cell lung?: pharmaranks lists 2 Programmed Death Receptor-1 Blocking Antibody products used for carcinoma, non-small-cell lung, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?: By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.